BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Merck Healthcare signs MoU with Rajiv Gandhi Cancer Institute and Research Centre

20 March 2024 | News

To enhance cancer care access through its flagship Umeed programme



Merck India, a leading science and technology company committed to supporting cancer patients, has announced a strategic partnership with Rajiv Gandhi Cancer Institute and Research Centre under the Umeed programme.

This collaborative initiative aims to bolster access to cancer care for patients affected by head & neck, and colorectal cancer. The Umeed Programme, rooted in a multifaceted approach, seeks to empower patients, foster awareness, and be a knowledge partner to healthcare professionals, thereby catalysing positive changes in the community.

Together with Rajiv Gandhi Cancer Institute and Research Centre, Merck will prioritise raising awareness and educating communities in identified Delhi districts about the signs, symptoms, timely diagnosis and management of head & neck and colorectal cancer. Merck Healthcare will facilitate counseling and screening events for patients, alongside providing subsidised diagnostic assistance through various supporting programs.

"With the cancer burden increasing in our country on a daily basis, through this collaborative endeavor, our aim is to offer a comprehensive programme that not only educates common man about Head and Neck Cancer but also facilitates higher screening, timely diagnosis, and access to treatment," stated Pratima Reddy, Country Speaker for Merck India & MD, Merck Specialties.

In alignment with Merck's global aspirations and commitment to expanding access to healthcare in the Low-and Middle-Income Countries (LMIC), the company has set an ambitious goal to touch 80 million patients by 2030 and make a positive impact on their lives.